A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Childrens Oncology Group phase I consortium study (ADVL0916)
Pediatric Blood & Cancer, 08/21/2012
Muscal JA et al. – The recommended Phase 2 dose and schedule is vorinostat (230mg/m2/day PO on days 1–5 and 8–12) in combination with bortezomib (1.3mg/m2/day i.v. on days 1, 4, 8, and 11 of a 21–day cycle) in children with recurrent or refractory solid tumors.